Petros Pharmaceuticals, Inc. Cash Provided by (Used in) Operating Activities, Discontinued Operations
Petros Pharmaceuticals, Inc. (PTPI) reported Cash Provided by (Used in) Operating Activities, Discontinued Operations of -$1.99 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Petros Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Petros Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-06-30 was -$1.83M.
- Petros Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-03-31 was -$165.50K.
- Petros Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2025 was -$1.99M, a 237.19% decline from fiscal 2024.
- Petros Pharmaceuticals, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2024 was $1.45M.
| Period end | Cash Provided by (Used in) Operating Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $0.00 derived: sum of 2 quarters · filed 2026-04-15 | -$1.83M derived: sum of 3 quarters · filed 2026-08-13 | -$1.99M 10-K · filed 2026-04-15 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.83M derived: sum of 2 quarters · filed 2026-08-13 | -$1.99M 10-Q · filed 2025-11-13 | -$635.29K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.99M 10-Q · filed 2026-08-13 | -$635.29K derived: sum of 3 quarters · filed 2026-08-13 | $52.23K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$165.50K 10-Q · filed 2026-05-13 | $1.19M derived: sum of 2 quarters · filed 2026-05-13 | $1.88M derived: sum of 3 quarters · filed 2026-05-13 | $1.38M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $2.04M derived: sum of 2 quarters · filed 2026-04-15 | $1.54M derived: sum of 3 quarters · filed 2026-04-15 | $1.45M 10-K · filed 2026-04-15 |
| 2024-09-30 | $687.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $186.21K derived: sum of 2 quarters · filed 2025-11-13 | $95.48K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$501.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$592.05K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$90.73K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |